Patents by Inventor David G. Hangauer, Jr.

David G. Hangauer, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240050438
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
    Type: Application
    Filed: February 16, 2023
    Publication date: February 15, 2024
    Inventor: David G. HANGAUER, JR.
  • Publication number: 20230167060
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention also relates to substantially pure compound 1 and substantially pure compound 1 salt (e.g., compound 1 hydrochloride salt and compound 1 benzenesulfonate salt). The invention further relates to methods of preparing substantially pure compound 1 and compound 1 salts.
    Type: Application
    Filed: September 29, 2022
    Publication date: June 1, 2023
    Inventor: David G. HANGAUER, JR.
  • Publication number: 20220160672
    Abstract: The invention relates to a pharmaceutical composition comprising 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: September 29, 2021
    Publication date: May 26, 2022
    Inventor: David G. Hangauer, JR.
  • Publication number: 20220119347
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
    Type: Application
    Filed: August 31, 2021
    Publication date: April 21, 2022
    Inventor: David G. HANGAUER, JR.
  • Publication number: 20210347763
    Abstract: The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
    Type: Application
    Filed: December 8, 2020
    Publication date: November 11, 2021
    Inventors: Michael P. SMOLINSKI, Sameer URGAONKAR, James Lindsay CLEMENTS, David G. HANGAUER, JR.
  • Publication number: 20210252008
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
    Type: Application
    Filed: January 19, 2021
    Publication date: August 19, 2021
    Inventor: David G. HANGAUER, JR.
  • Publication number: 20210214305
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention also relates to substantially pure compound 1 and substantially pure compound 1 salt (e.g., compound 1 hydrochloride salt and compound 1 benzenesulfonate salt). The invention further relates to methods of preparing substantially pure compound 1 and compound 1 salts.
    Type: Application
    Filed: August 24, 2020
    Publication date: July 15, 2021
    Inventor: David G. HANGAUER, Jr.
  • Publication number: 20210196724
    Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
    Type: Application
    Filed: March 1, 2021
    Publication date: July 1, 2021
    Inventors: Michael P. SMOLINSKI, Nader N. NASIEF ABDEL SAYED, David G. HANGAUER, JR.
  • Publication number: 20210198202
    Abstract: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morphohnoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present invention also provides a novel polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.
    Type: Application
    Filed: March 17, 2021
    Publication date: July 1, 2021
    Inventors: David G. HANGAUER, JR., Debasis PATRA, Jeremy A. CODY, Grant J. PALMER, Paul K. ISBESTER, Jonathon SALSBURY
  • Patent number: 10973828
    Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: April 13, 2021
    Assignee: Athenex, Inc.
    Inventors: Michael P. Smolinski, Nader N. Nasief Abdel-Sayed, David G. Hangauer, Jr.
  • Patent number: 10899747
    Abstract: The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: January 26, 2021
    Assignee: Athenex, Inc.
    Inventors: Michael P. Smolinski, Sameer Urgaonkar, James Lindsay Clements, David G. Hangauer, Jr.
  • Publication number: 20200071305
    Abstract: The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
    Type: Application
    Filed: September 11, 2019
    Publication date: March 5, 2020
    Inventors: Michael P. SMOLINSKI, Sameer URGAONKAR, James Lindsay CLEMENTS, David G. HANGAUER, JR.
  • Publication number: 20190367456
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade.
    Type: Application
    Filed: December 26, 2018
    Publication date: December 5, 2019
    Inventor: David G. HANGAUER, JR.
  • Patent number: 10450303
    Abstract: The present application is directed to biaryl piperidine amide compounds, or pharmaceutically acceptable salts, solvates, and prodrugs thereof, and methods of use thereof.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: October 22, 2019
    Assignee: Athenex, Inc.
    Inventors: Michael P. Smolinski, Sameer Urgaonkar, James Lindsay Clements, David G. Hangauer, Jr.
  • Publication number: 20190263755
    Abstract: The invention relates to compounds and methods for modulating one or more components of a kinase cascade. The invention also relats to substantially pure compound 1 and substantially pure compound 1 salt (e.g., compound 1 hydrochloride salt and compound 1 benzenesulfonate salt). The invention further relates to methods of preparing substantially pure compound 1 and compound 1 salts.
    Type: Application
    Filed: May 10, 2019
    Publication date: August 29, 2019
    Inventor: David G. HANGAUER, JR.
  • Publication number: 20190256468
    Abstract: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present invention also provides a novel polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a unique X-ray diffraction pattern and Differential Scanning calorimetry profile, as well as a unique crystalline structure.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 22, 2019
    Inventors: David G. HANGAUER, JR., Debasis PATRA, Jeremy A. CODY, Grant J. PALMER, Paul K. ISBESTER, Jonathon SALSBURY
  • Patent number: 10323001
    Abstract: The invention relates to compositions comprising 2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts. The invention provides an efficient process for the synthesis of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide and its mesylate and dihydrochloride salts and methods for modulating one or more components of a kinase cascade using the compositions of the invention. The present invention also provides a novel polymorph of the mesylate salt of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide (Form A), characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well as a unique crystalline structure.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: June 18, 2019
    Assignee: Athenex, Inc.
    Inventors: David G. Hangauer, Jr., Debasis Patra, Jeremy A. Cody, Grant J. Palmer, Paul K. Isbester, Jonathon Salsbury
  • Publication number: 20190125754
    Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
    Type: Application
    Filed: December 26, 2018
    Publication date: May 2, 2019
    Inventors: Michael P. SMOLINSKI, Nader N. NASIEF ABDEL-SAYED, David G. HANGAUER, JR.
  • Patent number: 10213435
    Abstract: The application relates to biaryl compounds, pharmaceutical compositions comprising the compounds, and methods of use the compounds for treating cell proliferation disorders.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: February 26, 2019
    Assignee: Athenex, Inc.
    Inventors: Michael P. Smolinski, Nader N. Nasief Abdel-Sayed, David G. Hangauer, Jr.
  • Patent number: 10196357
    Abstract: The invention relates to compounds of formula IB and methods for modulating one or more components of a kinase cascade using these compounds.
    Type: Grant
    Filed: April 14, 2008
    Date of Patent: February 5, 2019
    Assignee: Athenex, Inc.
    Inventor: David G. Hangauer, Jr.